» Articles » PMID: 28678775

Cryo-EM Structures of Tau Filaments from Alzheimer's Disease

Overview
Journal Nature
Specialty Science
Date 2017 Jul 6
PMID 28678775
Citations 909
Authors
Affiliations
Soon will be listed here.
Abstract

Alzheimer's disease is the most common neurodegenerative disease, and there are no mechanism-based therapies. The disease is defined by the presence of abundant neurofibrillary lesions and neuritic plaques in the cerebral cortex. Neurofibrillary lesions comprise paired helical and straight tau filaments, whereas tau filaments with different morphologies characterize other neurodegenerative diseases. No high-resolution structures of tau filaments are available. Here we present cryo-electron microscopy (cryo-EM) maps at 3.4-3.5 Å resolution and corresponding atomic models of paired helical and straight filaments from the brain of an individual with Alzheimer's disease. Filament cores are made of two identical protofilaments comprising residues 306-378 of tau protein, which adopt a combined cross-β/β-helix structure and define the seed for tau aggregation. Paired helical and straight filaments differ in their inter-protofilament packing, showing that they are ultrastructural polymorphs. These findings demonstrate that cryo-EM allows atomic characterization of amyloid filaments from patient-derived material, and pave the way for investigation of a range of neurodegenerative diseases.

Citing Articles

Probe-dependent Proximity Profiling (ProPPr) Uncovers Similarities and Differences in Phospho-Tau-Associated Proteomes Between Tauopathies.

Morderer D, Wren M, Liu F, Kouri N, Maistrenko A, Khalil B Mol Neurodegener. 2025; 20(1):32.

PMID: 40082954 PMC: 11905455. DOI: 10.1186/s13024-025-00817-0.


Tau filaments with the Alzheimer fold in human MAPT mutants V337M and R406W.

Qi C, Lovestam S, Murzin A, Peak-Chew S, Franco C, Bogdani M Nat Struct Mol Biol. 2025; .

PMID: 40044789 DOI: 10.1038/s41594-025-01498-5.


Limitations and Applications of Rodent Models in Tauopathy and Synucleinopathy Research.

Szegvari E, Holec S, Woerman A J Neurochem. 2025; 169(3):e70021.

PMID: 40026260 PMC: 11874209. DOI: 10.1111/jnc.70021.


Advancing Alzheimer's Therapy: Computational strategies and treatment innovations.

Paul J, Malik A, Azmal M, Gulzar T, Afghan M, Talukder O IBRO Neurosci Rep. 2025; 18:270-282.

PMID: 39995567 PMC: 11849200. DOI: 10.1016/j.ibneur.2025.02.002.


Quantitative chemoproteomics reveals dopamine's protective modification of Tau.

Wang Q, Liu Z, Wang Y, Liu Y, Chen Y, Zhang S Nat Chem Biol. 2025; .

PMID: 39979588 DOI: 10.1038/s41589-025-01849-9.


References
1.
Jakes R, Novak M, Davison M, Wischik C . Identification of 3- and 4-repeat tau isoforms within the PHF in Alzheimer's disease. EMBO J. 1991; 10(10):2725-9. PMC: 452980. DOI: 10.1002/j.1460-2075.1991.tb07820.x. View

2.
Wasmer C, Lange A, Van Melckebeke H, Siemer A, Riek R, Meier B . Amyloid fibrils of the HET-s(218-289) prion form a beta solenoid with a triangular hydrophobic core. Science. 2008; 319(5869):1523-6. DOI: 10.1126/science.1151839. View

3.
Jicha G, Bowser R, Kazam I, Davies P . Alz-50 and MC-1, a new monoclonal antibody raised to paired helical filaments, recognize conformational epitopes on recombinant tau. J Neurosci Res. 1997; 48(2):128-32. DOI: 10.1002/(sici)1097-4547(19970415)48:2<128::aid-jnr5>3.0.co;2-e. View

4.
He S, Scheres S . Helical reconstruction in RELION. J Struct Biol. 2017; 198(3):163-176. PMC: 5479445. DOI: 10.1016/j.jsb.2017.02.003. View

5.
Poorkaj P, Muma N, Zhukareva V, Cochran E, Shannon K, Hurtig H . An R5L tau mutation in a subject with a progressive supranuclear palsy phenotype. Ann Neurol. 2002; 52(4):511-6. DOI: 10.1002/ana.10340. View